This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Immune Pharmaceuticals Ltd.
Drug Names(s): histamine dihydrochloride, Maxamine
Description: Ceplene (histamine dihydrochloride) is based on the naturally occurring molecule histamine. It has been shown to prevent the production and release of oxygen free radicals, thereby reducing oxidative stress.
Deal Structure: Maxamine was originally developed by Maxim Pharmaceuticals.
EpiCept and Maxim
In August 2000, Maxim announced that it entered into a comprehensive development collaboration with F. Hoffmann - La Roche for the development of Maxamine in combination with Pegasys, Roche's pegylated interferon-alpha agent.
In January 2006, EpiCept completed its merger with Maxim Pharmaceuticals.
EpiCept and Meda
In January 2010, EpiCept announced it entered into an exclusive commercialization agreement for Ceplene with Meda AB. Under the terms of the agreement, EpiCept will grant Meda the right to market Ceplene in Europe and several other countries including Japan, China, and Australia. EpiCept will receive a $3 million fee and an additional $2 million upon the first commercial launch of Ceplene in a major European market. Additional payments include a $5 million payment upon achievement of a regulatory milestone and up to $30 million in sales-based milestones that...See full deal structure in Biomedtracker
Partners: Roche Holding AG Mylan Inc.
Pink Sheet Maxim Ceplene fails melanoma study
Additional information available to subscribers only: